Previous 10 | Next 10 |
Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor control Preclinical data also expand evidence on arenaviral immunotherapy targeting tumor self-antigens, reinforcing scientific appro...
NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in investor me...
Gainers: Lulu's Fashion Lounge Holdings (LVLU) +12%. Chicken Soup for the Soul Entertainment (CSSE) +8%. American Outdoor Brands (AOUT) +7%. Immuneering Corporation (IMRX) +6%. Service Properties Trust (SVC) +5%. Losers: Spero Therapeutics (SPRO) -24%. Duck Creek Tech...
Several data readouts of HB-200 alone and in combination with KEYTRUDA for treatment of HPV16+ HNSCC patients are expected in 2022. An amended agreement with Gilead Sciences, for arenavirus platform to develop treatments for HIV and HBV, established $54 million in commitment cash. ...
HOOKIPA Pharma Inc. (HOOK) Q4 2021 Earnings Conference Call March 24, 2022 08:30 AM ET Company Participants Matthew Beck - Executive Director, Investor Relations Joern Aldag - Chief Executive Officer Reinhard Kandera - Chief Financial Officer Igor Matushansky - Chief Medical Officer & Glo...
Gainers: BiondVax Pharmaceuticals (BVXV) +39%. Alpha Tau Medical (DRTS) +38%. CollPlant Biotechnologies (CLGN) +10%. Aptevo Therapeutics (APVO) +8%. HOOKIPA Pharma (HOOK) +8%. Losers: Sonendo (SONX) -11%. Creative Medical Technology (CELZ) -9%. Lan...
The following slide deck was published by HOOKIPA Pharma Inc. in conjunction with their 2021 Q4 earnings call. For further details see: HOOKIPA Pharma Inc. 2021 Q4 - Results - Earnings Call Presentation
Mercurity Fintech Holding (MFH) +65%. Fast Radius (FSRD) +21%. Nikola (NKLA) +18% after investor event. Femasys (FEMY) +13%. BiondVax Pharmaceuticals (BVXV) +13% on research pact to develop nanosized antibody therapies. Incannex Healthcare (IXHL) +12%. D-MARKET Elektronik&...
HOOKIPA Pharma press release (NASDAQ:HOOK): Q4 GAAP EPS of -$0.65 misses by $0.03. Revenue of $3.9M (-24.4% Y/Y) beats by $0.11M. The company expects to file an Investigational New Drug (IND) application for HB-300 in the third quarter of 2022. CEO comment: “With the recent capital rai...
Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patients HOOKIPA received FDA Fast Track designation and advanced HB-200 to Phase 2 trial in combination with pem...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...
2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com